Benza RL - Search Results

1

Pulmonary Hypertension: Intensification and Personalization of Combination Rx (PHoenix): A phase IV randomized trial for the evaluation of dose-response and clinical efficacy of riociguat and selexipag using implanted technologies.

Varian F, Dick J, Battersby C, Roman S, Ablott J, Watson L, Binmahfooz S, Zafar H, Colgan G, Cannon J, Suntharalingam J, Lordan J, Howard L, McCabe C, Wort J, Price L, Church C, Hamilton N, Armstrong I, Hameed A, Hurdman J, Elliot C, Condliffe R, Wilkins M, Webb A, Adlam D, Benza RL, Rahimi K, Shojaei-Shahrokhabadi M, Lin NX, Wason JMS, McIntosh A, McConnachie A, Middleton JT, Thompson R, Kiely DG, Toshner M, Rothman A. Varian F, et al. Among authors: benza rl. Pulm Circ. 2024 Mar 17;14(1):e12337. doi: 10.1002/pul2.12337. eCollection 2024 Jan. Pulm Circ. 2024. PMID: 38500737 Free PMC article.

2

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension.

Davey R, Benza RL, Murali S, Raina A. Davey R, et al. Among authors: benza rl. Pulm Circ. 2017 Apr-Jun;7(2):539-542. doi: 10.1177/2045893217708566. Epub 2017 May 12. Pulm Circ. 2017. PMID: 28597779 Free PMC article.

3

Assessment of the REPLACE study composite endpoint in riociguat-treated patients in the PATENT study.

Simonneau G, Ghofrani HA, Corris PA, Rosenkranz S, Grünig E, White J, McLaughlin VV, Langleben D, Meier C, Busse D, Kleinjung F, Benza RL. Simonneau G, et al. Among authors: benza rl. Pulm Circ. 2020 Dec 9;10(4):2045894020973124. doi: 10.1177/2045894020973124. eCollection 2020 Oct-Dec. Pulm Circ. 2020. PMID: 33354316 Free PMC article.

4

TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension.

Frantz RP, Benza RL, Channick RN, Chin K, Howard LS, McLaughlin VV, Sitbon O, Zamanian RT, Hemnes AR, Cravets M, Bruey JM, Roscigno R, Mottola D, Elman E, Zisman LS, Ghofrani HA. Frantz RP, et al. Among authors: benza rl. Pulm Circ. 2021 Nov 11;11(4):20458940211057071. doi: 10.1177/20458940211057071. eCollection 2021 Oct-Dec. Pulm Circ. 2021. PMID: 34790348 Free PMC article.

5

CS1, a controlled-release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial.

Benza RL, Adamson PB, Bhatt DL, Frick F, Olsson G, Bergh N, Dahlöf B. Benza RL, et al. Pulm Circ. 2024 Jan 3;14(1):e12323. doi: 10.1002/pul2.12323. eCollection 2024 Jan. Pulm Circ. 2024. PMID: 38174159 Free PMC article.

6

Hemodynamic response to treatment of iron deficiency anemia in pulmonary arterial hypertension: longitudinal insights from an implantable hemodynamic monitor.

Mehmood M, Agarwal R, Raina A, Correa-Jaque P, Benza RL. Mehmood M, et al. Among authors: benza rl. Pulm Circ. 2016 Dec;6(4):616-618. doi: 10.1086/688670. Pulm Circ. 2016. PMID: 28090307 Free PMC article.

7

Replacing a phosphodiesterase-5 inhibitor with riociguat in patients with connective tissue disease-associated pulmonary arterial hypertension: a case series.

Raina A, Benza RL, Farber HW. Raina A, et al. Among authors: benza rl. Pulm Circ. 2017 Jul-Sep;7(3):741-746. doi: 10.1177/2045893217721694. Epub 2017 Aug 3. Pulm Circ. 2017. PMID: 28671485 Free PMC article.

8

Association between cytokines and functional, hemodynamic parameters, and clinical outcomes in pulmonary arterial hypertension.

Joshi AA, Davey R, Rao Y, Shen K, Benza RL, Raina A. Joshi AA, et al. Among authors: benza rl. Pulm Circ. 2018 Jul-Sep;8(3):2045894018794051. doi: 10.1177/2045894018794051. Epub 2018 Jul 23. Pulm Circ. 2018. PMID: 30036135 Free PMC article.

9

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19.

Franco V, Bradley EA, Badagliacca R, Sabanayagam A, Rajpal S, Lastinger LT, Daniels CJ, Smith JS, Benza RL. Franco V, et al. Among authors: benza rl. Pulm Circ. 2020 Nov 20;10(4):2045894020970369. doi: 10.1177/2045894020970369. eCollection 2020 Oct-Dec. Pulm Circ. 2020. PMID: 33282201 Free PMC article.

10

Safety and efficacy of transitioning from the combination of bosentan and sildenafil to alternative therapy in patients with pulmonary arterial hypertension.

Verlinden NJ, Benza RL, Raina A. Verlinden NJ, et al. Among authors: benza rl. Pulm Circ. 2020 Dec 9;10(4):2045894020945523. doi: 10.1177/2045894020945523. eCollection 2020 Oct-Dec. Pulm Circ. 2020. PMID: 33354314 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

222 results

Search Page

Filters